Forbion has co-led a $372.5 million Series D financing for MapLight Therapeutics to advance its novel CNS disorder therapies, emphasizing a significant investment in biopharmaceutical innovation.

Target Information

MapLight Therapeutics is a pioneering clinical-stage biopharmaceutical firm dedicated to developing innovative therapies for central nervous system (CNS) disorders. Established by distinguished experts in psychiatry and neuroscience, the company specializes in identifying neural circuits that are causally linked to various diseases and creating targeted therapeutics that address these neural pathways. With a focus on conditions such as schizophrenia and Alzheimer’s disease psychosis, MapLight aims to significantly enhance the quality of life for patients and their families.

Industry Overview

The biopharmaceutical industry is witnessing a transformative phase, especially in Europe, where increasing investments are being funneled into developing advanced therapeutics for CNS disorders. Conditions such as schizophrenia and Alzheimer’s disease are among the leading contributors to global health burdens, representing a significant unmet medical need. With many traditional treatments offering limited efficacy and substantial side effects, there is a growing demand for innovative solutions that can provide better patient outcomes.

In recent years, the European biotech landscape has evolved markedly, with venture capital funding reaching unprecedented levels. In 2025 alone, substantial financings, like that of MapLight Therapeutics, showcase the c